These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10210231)

  • 1. Antisense and nuclear medicine.
    Hnatowich DJ
    J Nucl Med; 1999 Apr; 40(4):693-703. PubMed ID: 10210231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell culture and xenograft-bearing animal studies of radiolabeled antisense DNA carrier nanoparticles with streptavidin as a linker.
    Nakamura K; Wang Y; Liu X; Kubo A; Hnatowich DJ
    J Nucl Med; 2007 Nov; 48(11):1845-52. PubMed ID: 17978353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of antisense tumor targeting in mice.
    Nakamura K; Fan C; Liu G; Gupta S; He J; Dou S; Kubo A; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2004; 15(6):1475-80. PubMed ID: 15546217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging: an overview and clinical applications.
    Rollo FD
    Radiol Manage; 2003; 25(3):28-32; quiz 33-5. PubMed ID: 12817419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumor delivery.
    Hnatowic DJ; Nakamura K
    Curr Opin Mol Ther; 2006 Apr; 8(2):136-43. PubMed ID: 16610766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic considerations in the development of oligomers as radiopharmaceuticals.
    Hnatowich DJ
    Q J Nucl Med; 1997 Jun; 41(2):91-100. PubMed ID: 9203848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
    Schlag PM
    Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
    Cho-Chung YS
    Curr Opin Investig Drugs; 2002 Jun; 3(6):934-9. PubMed ID: 12137417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical antisense imaging of tumor with fluorescent DNA duplexes.
    Liu X; Wang Y; Nakamura K; Liu G; Dou S; Kubo A; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2007; 18(6):1905-11. PubMed ID: 17939728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: StealthVector (HIV) Enzo.
    Günzburg W; Mhashilkar AM; Hindi M
    Curr Opin Mol Ther; 1999 Oct; 1(5):651-7. PubMed ID: 11249672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense imaging: where are we now?
    Hnatowich DJ
    Cancer Biother Radiopharm; 2000 Oct; 15(5):447-57. PubMed ID: 11155817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.